Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  2. Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  3. Institute of Medical Science and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  4. Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  5. Neurocognitive Research Laboratory, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas
  6. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina
  7. Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  8. Institute of Medical Science and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  9. Institute of Medical Science and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  10. Centre for Mental Health and Krembil Research Institute, University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  11. Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  12. Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  13. Institute of Medical Science and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  14. Epworth Centre for Innovation in Mental Health, Epworth Healthcare and Monash University Department of Psychiatry, Camberwell, Victoria, Australia
  15. Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  16. Institute of Medical Science and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  17. Department of Psychiatry, UC San Diego Health, La Jolla, California
  18. Corresponding author: Zafiris J. Daskalakis, MD, PhD, Department of Psychiatry, UC San Diego Health, 9500 Gilman Drive, La Jolla CA 92093-0603 ([email protected]).
  1. Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004;161(1):163–165. PubMed CrossRef
  2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. PubMed CrossRef
  3. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–234. PubMed CrossRef
  4. Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med. 2007;357(19):1939–1945. PubMed CrossRef
  5. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568–577. PubMed CrossRef
  6. Lisanby SH, Luber B, Schlaepfer TE, et al. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology. 2003;28(10):1852–1865. PubMed CrossRef
  7. McClintock SM, Tirmizi O, Chansard M, et al. A systematic review of the neurocognitive effects of magnetic seizure therapy. Int Rev Psychiatry. 2011;23(5):413–423. PubMed CrossRef
  8. Kirov G, Ebmeier KP, Scott AI, et al. Quick recovery of orientation after magnetic seizure therapy for major depressive disorder. Br J Psychiatry. 2008;193(2):152–155. PubMed CrossRef
  9. Fitzgerald PB, Hoy KE, Elliot D, et al. A pilot study of the comparative efficacy of 100 Hz magnetic seizure therapy and electroconvulsive therapy in persistent depression. Depress Anxiety. 2018;35(5):393–401. PubMed CrossRef
  10. Deng Z-D, Lisanby SH, Peterchev AV. Electric field strength and focality in electroconvulsive therapy and magnetic seizure therapy: a finite element simulation study. J Neural Eng. 2011;8(1):016007. PubMed CrossRef
  11. Lee WH, Lisanby SH, Laine AF, et al. Comparison of electric field strength and spatial distribution of electroconvulsive therapy and magnetic seizure therapy in a realistic human head model. Eur Psychiatry. 2016;36:55–64. PubMed CrossRef
  12. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285(10):1299–1307. PubMed CrossRef
  13. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry. 2006;63(12):1337–1344. PubMed CrossRef
  14. Nordenskjöld A, von Knorring L, Ljung T, et al. Continuation electroconvulsive therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression: a randomized controlled trial. J ECT. 2013;29(2):86–92. PubMed CrossRef
  15. Navarro V, Gastó C, Torres X, et al. Continuation/maintenance treatment with nortriptyline versus combined nortriptyline and ECT in late-life psychotic depression: a two-year randomized study. Am J Geriatr Psychiatry. 2008;16(6):498–505. PubMed CrossRef
  16. Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology. 2013;38(12):2467–2474. PubMed CrossRef
  17. Kellner CH, Husain MM, Knapp RG, et al; CORE/PRIDE Work Group. A novel strategy for continuation ECT in geriatric depression: phase 2 of the PRIDE study. Am J Psychiatry. 2016;173(11):1110–1118. PubMed CrossRef
  18. Kayser S, Bewernick BH, Matusch A, et al. Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects. Psychol Med. 2015;45(5):1073–1092. PubMed CrossRef
  19. Daskalakis ZJ, Dimitrova J, McClintock SM, et al. Magnetic seizure therapy (MST) for major depressive disorder. Neuropsychopharmacology. 2020;45(2):276–282. PubMed CrossRef
  20. Tang VM, Blumberger DM, Dimitrova J, et al. Magnetic seizure therapy is efficacious and well tolerated for treatment-resistant bipolar depression: an open-label clinical trial. J Psychiatry Neurosci. 2020;45(5):313–321. PubMed CrossRef
  21. Hamilton M. Rating depressive patients. J Clin Psychiatry. 1980;41(12 pt 2):21–24. PubMed
  22. First MH, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders—Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 1990.
  23. First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID II). New York: Biometric Research Department; 1994.
  24. Oquendo MA, Baca-Garcia E, Kartachov A, et al. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry. 2003;64(7):825–833. PubMed CrossRef
  25. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
  26. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979;47(2):343–352. PubMed CrossRef
  27. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429–435. PubMed CrossRef
  28. McElhiney M, Moody B, Sackeim H. The Autobiographical Memory Interview-Short form. New York: Department of Biological Psychiatry: New York State Psychiatric Institute; 2001.
  29. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. PubMed CrossRef
  30. Partington JE, Leiter RG. Partington’s Pathways Test. Psychol Serv Cent J. 1949;1:11–20.
  31. Golden CJ, Freshwater SM. Stroop Color and Word Test. 1978. https://link.springer.com/referenceworkentry/10.1007%2F978-0-387-79948-3_660
  32. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. Oxford University Press; 1998.
  33. Nuechterlein KH, Green MF. MATRICS Consensus Cognitive Battery Manual. Los Angeles, CA: MATRICS Assessment Inc; 2006.
  34. Polster JD, Kayser S, Bewernick BH, et al. Effects of electroconvulsive therapy and magnetic seizure therapy on acute memory retrieval. J ECT. 2015;31(1):13–19. PubMed CrossRef
  35. Sun Y, Blumberger DM, Mulsant BH, et al. Magnetic seizure therapy reduces suicidal ideation and produces neuroplasticity in treatment-resistant depression. Transl Psychiatry. 2018;8(1):253. PubMed CrossRef
  36. Patel RS, Bachu A, Youssef NA. Combination of lithium and electroconvulsive therapy (ECT) is associated with higher odds of delirium and cognitive problems in a large national sample across the United States. Brain Stimul. 2020;13(1):15–19. PubMed CrossRef
  37. Prudic J, Haskett RF, McCall WV, et al. Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. J ECT. 2013;29(1):3–12. PubMed CrossRef
  38. Elias A, Phutane VH, Clarke S, et al. Electroconvulsive therapy in the continuation and maintenance treatment of depression: systematic review and meta-analyses. Aust N Z J Psychiatry. 2018;52(5):415–424. PubMed CrossRef
  39. Sackeim HA, Prudic J, Devanand DP, et al. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990;10(2):96–104. PubMed CrossRef
  40. Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57(5):425–434. PubMed CrossRef
  41. Omori W, Itagaki K, Kajitani N, et al. Shared preventive factors associated with relapse after a response to electroconvulsive therapy in four major psychiatric disorders. Psychiatry Clin Neurosci. 2019;73(8):494–500. PubMed CrossRef
  42. Semkovska M, McLoughlin DM. Measuring retrograde autobiographical amnesia following electroconvulsive therapy: historical perspective and current issues. J ECT. 2013;29(2):127–133. PubMed CrossRef
  43. Kessler U, Schoeyen HK, Andreassen OA, et al. The effect of electroconvulsive therapy on neurocognitive function in treatment-resistant bipolar disorder depression. J Clin Psychiatry. 2014;75(11):e1306–e1313. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe now